Cancer glossary
NGS panel in cancer care: what it is and how to read the report
What an NGS panel is in cancer: how it differs from PCR, which tumors ESMO recommends it for, and how to read a report listing mutations, MSI and TMB.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
NGS (next-generation sequencing) is a method that checks dozens or hundreds of tumor genes in a single test. The panel looks for changes that targeted drugs or immunotherapy act on, and it uses less tissue than testing one gene after another.
How it appears in your report
An NGS report is usually longer than a standard pathology report. Typical parts:
- ‘EGFR p.L858R mutation detected, variant allele frequency 23%’ — the change itself and the share of DNA molecules carrying it.
- ‘EML4-ALK gene fusion’ — a rearrangement that targeted drugs act on.
- ‘MSS; TMB 4 mut/Mb’ — microsatellite instability status and tumor mutational burden.
- ‘Variants of uncertain significance’ — changes whose meaning is not yet clear.
- ‘Tumor cell content of the sample: 30%’ — this affects how reliable the result is.
What it means
ESMO recommends routine tumor NGS for these metastatic cancers:
| Year of recommendation | Cancers |
|---|---|
| 2020 | non-squamous non-small cell lung cancer, prostate cancer, ovarian cancer, cholangiocarcinoma |
| 2024 (added) | HR-positive HER2-negative breast cancer, GIST, sarcoma, thyroid cancer, cancer of unknown primary |
ESMO also lists ‘tumor-agnostic’ targets that matter wherever the cancer started: NTRK, RET and FGFR fusions, BRAF V600E, MSI-H and high TMB. In colorectal cancer, NGS can be used instead of PCR.
Does it affect treatment
It can. A finding such as EGFR or ALK changes first-line treatment; BRCA in the tumor is a reason to discuss PARP inhibitors and inherited testing. But if there is no target, or the matching drug is not available, the report may not change the plan. ESMO advises tumor-agnostic testing where the matching drugs are accessible. Your treating doctor decides which findings matter for you.
Questions to ask your doctor
- Which genes were on the panel — DNA, RNA or both?
- Which of the findings matter for my treatment?
- Do any of them mean my relatives should be tested?
More in the article on mutations in lung cancer. If you have an NGS report, I can go through it with you in a consultation.
Sources
Watch me explain this on video
Short videos on my Instagram (in Russian)
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
